A Case of IDH ‐Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant
Neuropathology · 2026-04 · 46 (2)
DOI: 10.1111/neup.70048 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuropathology, online erschienen am 24.02.2026. Verfasst von Thomas Auen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Astrocytoma, Brain Neoplasms. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
IDH‐mutant gliomas most commonly harbor the canonical IDH1 p.R132H mutation, followed by less common mutations involving IDH1 p.R132 or IDH2 p.R172 codons. We present a case of a 32‐year‐old male found to have a left temporal brain tumor with regional enhancement on brain MRI, for which he underwent resection. Histologic sections showed an infiltrating astrocytic tumor with increased mitotic activity and elevated Ki67 (MIB1) labeling. The tumor was negative for IDH1 p.R132H mutant protein expression with retained ATRX expression. 1p/19q was intact by FISH analysis, and next‐generation sequencing identified a previously unreported IDH2 (p.R172_H173delinsSN) likely pathogenic variant. A diagnosis of astrocytoma, IDH‐mutant, CNS WHO grade 3 was rendered. Subsequent tumor methylation profiling performed at the National Institutes of Health matched with high confidence to the class “IDH glioma, subclass astrocytoma” and confirmed lack of MGMT promoter hypermethylation. He received adjuvant concurrent radiation and temozolomide. Surveillance brain MRI at 32 months post resection demonstrated no evidence of interval tumor progression. We present a case of IDH‐mutant astrocytoma with a somewhat atypical molecular presentation, including a previously uncharacterized IDH2 mutation, retained ATRX expression, and lack of MGMT promoter hypermethylation. Though it has not been biochemically or functionally validated, tumor methylation profiling is supportive of this previously uncharacterized IDH2 variant as tumorigenic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID-Profile: Thomas Auen
Zitieren
APA
Auen, T., Chen, J., Shonka, N., & Cathcart, S. (2026). A Case of IDH ‐Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant. Neuropathology, 46(2). https://doi.org/10.1111/neup.70048
Vancouver
Auen T, Chen J, Shonka N, Cathcart S. A Case of IDH ‐Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant. Neuropathology. 2026;46(2). doi:10.1111/neup.70048
BibTeX
@article{Auen2026,
author = {Auen, Thomas and Chen, Jie and Shonka, Nicole and Cathcart, Sahara},
title = {A Case of IDH ‐Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant},
journal = {Neuropathology},
year = {2026},
volume = {46},
number = {2},
doi = {10.1111/neup.70048}
}
EUVIMED